• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

依诺肝素与普通肝素治疗抗磷脂抗体综合征所致复发性流产的疗效比较。

Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.

机构信息

Department of Obstetrics and Gynecology, Faculty of medicine, Cairo University, Cairo, Egypt.

出版信息

Int J Gynaecol Obstet. 2011 Mar;112(3):211-5. doi: 10.1016/j.ijgo.2010.09.010. Epub 2011 Jan 19.

DOI:10.1016/j.ijgo.2010.09.010
PMID:21251653
Abstract

OBJECTIVE

To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS).

METHODS

In a randomized prospective study, 60 women with a history of 3 or more consecutive spontaneous abortions and positive antiphospholipid antibodies were assigned in equal numbers to receive either UFH (5000 units, twice daily) plus LDA, or LMWH (enoxaparin 40 mg, once daily) plus LDA as soon as pregnancy was diagnosed.

RESULTS

Twenty-four women in the LMWH group (80%) and 20 women in the UFH group (66.67%) delivered a viable infant (P = 0.243). There were no significant differences in pregnancy complications or neonatal morbidity between the 2 groups. There were no incidences of excessive bleeding, thrombocytopenia, or osteoporotic fractures in either group.

CONCLUSION

LMWH plus LDA was successfully used as an alternative to UFH plus LDA in the management of recurrent abortion secondary to APS. The results highlight the need for a larger randomized controlled trial to determine whether LMWH plus LDA should be the treatment of choice for recurrent abortion secondary to APS. Clinicaltrials.gov NCT01051778.

摘要

目的

确定低分子量肝素(LMWH)联合小剂量阿司匹林(LDA)与普通肝素(UFH)联合 LDA 在治疗因抗磷脂综合征(APS)导致复发性自发性流产史的孕妇中的疗效和安全性是否相当。

方法

在一项随机前瞻性研究中,将 60 名有 3 次或以上连续自发性流产史且抗磷脂抗体阳性的女性等分为两组,分别给予 UFH(5000 单位,每日两次)联合 LDA 或 LMWH(依诺肝素 40mg,每日一次)联合 LDA,一旦确诊怀孕即开始治疗。

结果

LMWH 组 24 名女性(80%)和 UFH 组 20 名女性(66.67%)成功分娩出活婴(P=0.243)。两组的妊娠并发症或新生儿发病率无显著差异。两组均未发生过度出血、血小板减少或骨质疏松性骨折。

结论

LMWH 联合 LDA 可成功替代 UFH 联合 LDA 用于治疗因 APS 导致的复发性流产。研究结果强调需要进行更大规模的随机对照试验,以确定 LMWH 联合 LDA 是否应成为因 APS 导致的复发性流产的首选治疗方法。Clinicaltrials.gov NCT01051778。

相似文献

1
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.依诺肝素与普通肝素治疗抗磷脂抗体综合征所致复发性流产的疗效比较。
Int J Gynaecol Obstet. 2011 Mar;112(3):211-5. doi: 10.1016/j.ijgo.2010.09.010. Epub 2011 Jan 19.
2
Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.与复发性流产相关的抗磷脂抗体:比较低分子量肝素与普通肝素治疗的前瞻性、多中心、对照性初步研究
Fertil Steril. 2005 Mar;83(3):684-90. doi: 10.1016/j.fertnstert.2004.11.002.
3
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.阿司匹林或肝素或两者联合用于改善患有持续性抗磷脂抗体和复发性流产的女性的妊娠结局。
Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2.
4
Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome.两剂低分子量肝素(依诺肝素)用于抗磷脂综合征继发复发性流产孕妇的疗效与安全性。
J Obstet Gynaecol. 2010;30(8):842-6. doi: 10.3109/01443615.2010.518651.
5
Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials.阿司匹林或肝素或两者联合用于抗磷脂抗体综合征女性复发性自然流产的治疗:一项随机对照试验的荟萃分析
J Matern Fetal Neonatal Med. 2019 Apr;32(8):1299-1311. doi: 10.1080/14767058.2017.1404979. Epub 2018 Jan 10.
6
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.低分子量肝素与华法林用于抗磷脂综合征患者孕期治疗
Thromb Haemost. 2001 Dec;86(6):1379-84.
7
Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin.使用低剂量阿司匹林和肝素治疗的、与抗磷脂抗体相关的复发性流产女性的妊娠并发症。
Br J Obstet Gynaecol. 1999 Feb;106(2):102-7. doi: 10.1111/j.1471-0528.1999.tb08208.x.
8
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.阿司匹林和/或肝素用于患有或不患有遗传性血栓形成倾向的不明原因复发性流产女性。
Cochrane Database Syst Rev. 2014 Jul 4;2014(7):CD004734. doi: 10.1002/14651858.CD004734.pub4.
9
Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome).肝素或阿司匹林或两者联合治疗抗磷脂抗体(综合征)妇女复发性流产。
Curr Opin Rheumatol. 2011 May;23(3):299-304. doi: 10.1097/BOR.0b013e328344c3f7.
10
Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis.抗磷脂抗体综合征相关复发性妊娠丢失的治疗干预措施比较:系统评价和网络荟萃分析。
Am J Reprod Immunol. 2020 Apr;83(4):e13219. doi: 10.1111/aji.13219. Epub 2020 Jan 28.

引用本文的文献

1
Warfarin and heparin monitoring in antiphospholipid syndrome.抗磷脂综合征中华法林和肝素的监测
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):192-199. doi: 10.1182/hematology.2024000547.
2
The pathogenesis of obstetric APS: a 2023 update.产科抗磷脂综合征的发病机制:2023 年更新。
Clin Immunol. 2023 Oct;255:109745. doi: 10.1016/j.clim.2023.109745. Epub 2023 Aug 23.
3
Effect of low-molecular-weight heparin in women undergoing frozen-thawed embryo transfer cycles: a retrospective cohort study.低分子肝素对冻融胚胎移植周期妇女的影响:一项回顾性队列研究。
BMC Pregnancy Childbirth. 2023 May 10;23(1):335. doi: 10.1186/s12884-023-05634-1.
4
Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome.抗磷脂综合征中血栓形成、妊娠并发症或死亡的风险
Front Cardiovasc Med. 2022 Mar 1;9:852777. doi: 10.3389/fcvm.2022.852777. eCollection 2022.
5
Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome-What is the evidence?抗磷脂抗体综合征反复妊娠丢失的抗栓治疗:有何证据?
J Thromb Haemost. 2021 May;19(5):1174-1185. doi: 10.1111/jth.15290. Epub 2021 Mar 26.
6
Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis.抗磷脂抗体综合征产科患者中预防胎儿生长受限的治疗方法比较:系统评价和网络荟萃分析。
Intern Emerg Med. 2021 Aug;16(5):1357-1367. doi: 10.1007/s11739-020-02609-4. Epub 2021 Jan 21.
7
Role of Low Molecular Weight Heparin in the Management of Unexplained Recurrent Pregnancy Loss: A Review of Literature.低分子量肝素在不明原因复发性流产管理中的作用:文献综述
Cureus. 2020 Oct 15;12(10):e10956. doi: 10.7759/cureus.10956.
8
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.阿司匹林或肝素或两者联合用于改善患有持续性抗磷脂抗体和复发性流产的女性的妊娠结局。
Cochrane Database Syst Rev. 2020 May 2;5(5):CD012852. doi: 10.1002/14651858.CD012852.pub2.
9
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.依诺肝素在妊娠期的安全性和疗效:系统评价和荟萃分析。
Adv Ther. 2020 Jan;37(1):27-40. doi: 10.1007/s12325-019-01124-z. Epub 2019 Oct 31.
10
Idiopathic Normal Pressure Hydrocephalus - What We Know.特发性正常压力脑积水——我们所了解的情况。
Maedica (Bucur). 2019 Jun;14(2):161-164. doi: 10.26574/maedica.2019.14.2.161.